Overexpression of heparan sulfate 6‑O‑sulfotransferase‑2 in colorectal cancer

  • Authors:
    • Shigeru Hatabe
    • Hideharu Kimura
    • Tokuzo Arao
    • Hiroaki Kato
    • Hidetoshi Hayashi
    • Tomoyuki Nagai
    • Kazuko Matsumoto
    • Marco De Velasco
    • Yoshihiko Fujita
    • Go Yamanouchi
    • Masao Fukushima
    • Yasuhide Yamada
    • Akihiko Ito
    • Kiyotaka Okuno
    • Kazuto Nishio
  • View Affiliations

  • Published online on: July 23, 2013     https://doi.org/10.3892/mco.2013.151
  • Pages: 845-850
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The heparan sulfate sulfotransferase gene family catalyzes the transfer of sulfate groups to heparan sulfate and regulates various growth factor‑receptor signaling pathways. however, the involvement of this gene family in cancer biology has not been elucidated. It was demonstrated that the heparan sulfate D‑glucosaminyl 6‑O‑sulfotransferase‑2 (HS6ST2) gene is overexpressed in colorectal cancer (CRC) and its clinical significance in patients with CRC was investigated. The mRNA levels of HS6ST2 in clinical CRC samples and various cancer cell lines were assessed using a microarray analysis and quantitative RT‑PCR, respectively. An immunohistochemical (IHC) analysis of the HS6ST2 protein was performed using 102 surgical specimens of CRC. The correlations between the HS6ST2 expression status and clinicopathological characteristics were then evaluated. HS6ST2 mRNA was significantly overexpressed by 37‑fold in CRC samples compared to paired colonic mucosa. High levels of HS6ST2 mRNA expression were also observed in colorectal, esophageal and lung cancer cell lines. the IHC analysis demonstrated that HS6ST2 was expressed in the cytoplasmic region of CRC cells, but not in normal colonic mucosal cells. Positive staining for HS6ST2 was detected in 40 patients (39.2%). There was no significant association between the clinicopathological characteristics and HS6ST2 expression. However, positive staining for HS6ST2 was associated with a poor survival (P=0.074, log‑rank test). In conclusion, HS6ST2 was found to be overexpressed in CRC and its expression tended to be a poor prognostic factor, although the correlation was not significant. These findings indicate that HS6ST2 may be a novel cancer‑related marker that may provide insight into the glycobiology of CRC.
View Figures
View References

Related Articles

Journal Cover

September 2013
Volume 1 Issue 5

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Hatabe, S., Kimura, H., Arao, T., Kato, H., Hayashi, H., Nagai, T. ... Nishio, K. (2013). Overexpression of heparan sulfate 6‑O‑sulfotransferase‑2 in colorectal cancer. Molecular and Clinical Oncology, 1, 845-850. https://doi.org/10.3892/mco.2013.151
MLA
Hatabe, S., Kimura, H., Arao, T., Kato, H., Hayashi, H., Nagai, T., Matsumoto, K., De Velasco, M., Fujita, Y., Yamanouchi, G., Fukushima, M., Yamada, Y., Ito, A., Okuno, K., Nishio, K."Overexpression of heparan sulfate 6‑O‑sulfotransferase‑2 in colorectal cancer". Molecular and Clinical Oncology 1.5 (2013): 845-850.
Chicago
Hatabe, S., Kimura, H., Arao, T., Kato, H., Hayashi, H., Nagai, T., Matsumoto, K., De Velasco, M., Fujita, Y., Yamanouchi, G., Fukushima, M., Yamada, Y., Ito, A., Okuno, K., Nishio, K."Overexpression of heparan sulfate 6‑O‑sulfotransferase‑2 in colorectal cancer". Molecular and Clinical Oncology 1, no. 5 (2013): 845-850. https://doi.org/10.3892/mco.2013.151